Figure 3.
Overall survival (OS) from start of lenalidomide treatment for AML/MDS, NHM and non‐SPM groups. Two‐year OS was 83.33% (95% CI, 27.31–97.47%) in the MDS/AML group, 80% (CI 20.38–96.92%) in the NHM group and 39.89% (CI 32.74–46.93%) in the Non‐SPM group, Log‐rank P = 0.24 Wilcoxon P = 0.14.